PBLS vs TNGX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PBLS · Parabilis Medicines$27.44 ▼ 0.67%
TNGX · Tango Therapeutics$21.73 ▼ 4.32%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PBLS -13.2%
- TNGX -24.2%
Head to head
| Metric | PBLS | TNGX |
|---|---|---|
| Price | $27.44 | $21.73 |
| Change today | ▼ 0.67% | ▼ 4.32% |
| Market cap | $3.44B | $3.68B |
| Return, 3 months | -28.6% | -11.3% |
| Return, year to date | – | +145.3% |
| Return, 1 year | – | +116.7% |
| P/E (TTM) | – | – |
| P/B | 3.4 | 3.8 |
| P/E percentile vs own 5y | 75th | 14th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -100.0% |
| Net profit growth (YoY) | -50.7% | -530.6% |
| Gross margin | – | – |
| Operating margin | -117,335.8% | – |
| Net margin | -156,531.8% | – |
| Return on equity | -22.1% | -36.5% |
| Analyst target vs. price | +50.6% | +124.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 45 | 44 |
| 30-day volatility | 84.7% | 95.4% |
| Max drawdown, 1 year | -45.5% | -36.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TNGX is the largest of the group by market value.
- PBLS has been the calmest stock over the last 30 days.